Abstract
Galium-68 prostate-specific membrane antigen positron emission tomography combined with computed tomography (68Ga PSMA PET-CT) is receptor specific imaging, which has increasingly been used in the staging and restaging of prostate carcinoma (PCa). PSMA is type II transmembrane glycoprotein expressed in cytosol of normal prostatic tissue with 100-1000-fold over expression in PCa. It is also expressed in the endothelium of tumor-associated neo vasculature of non-prostatic solid tumor such as transitional cell and renal cell carcinoma, hepatocellular, thyroid, and brain cancers. We hereby present a case where PSMA PET scan showed three tumors proved on follow up imaging.
Keywords:
68Ga PSMA PET-CT, prostate carcinoma, hepatocellular carcinoma, meningioma
Ethics
Informed Consent: Exemption of informed consent was sought from the institutional review board (IRB) [Exemption number- EX-29-04-20-04] based on the following points: a) It is a retrospective study, and information in this study is currently in existence in the hospital information system. b) The information is recorded in such a manner that the subjects cannot be identified. c) There would be no contact with the patient.
Authorship Contributions
Surgical and Medical Practices: S.M.G., A.H., W.A., I.U.D., Concept: S.M.G., W.A., Design: S.M.G., A.H., Data Collection or Processing: S.M.G., Analysis or Interpretation: S.M.G., A.H., W.A., I.U.D., Literature Search: S.M.G., Writing: S.M.G., A.H., W.A., I.U.D.
Conflict of Interest: No conflicts of interest were declared by the authors.
Financial Disclosure: The authors declare that this study has received no financial support.
References
1
Jadvar H, Calais J, Fanti S, Feng F, Greene KL, Gulley JL, Hofman M, Koontz BF, Lin DW, Morris MJ, Rowe SP, Royce TJ, Salami S, Savir-Baruch B, Srinivas S, Hope TA. appropriate use criteria for prostate-specific membrane antigen PET imaging. J Nucl Med. 2022;63:59-68.
2
Jochumsen MR, Bouchelouche K. PSMA PET/CT for primary staging of prostate cancer - an updated overview. Semin Nucl Med. 2024;54:39-45.
3
Kopka K, Benešová M, Bařinka C, Haberkorn U, Babich J. Glu-ureido-based inhibitors of prostate-specific membrane antigen: lessons learned during the development of a novel class of low-molecular-weight theranostic radiotracers. J Nucl Med. 2017;58:17S-26S.
4
Lisney AR, Leitsmann C, Strauß A, Meller B, Bucerius JA, Sahlmann CO. The role of PSMA PET/CT in the primary diagnosis and follow-up of prostate cancer-a practical clinical review. Cancers (Basel). 2022;14:3638.
5
Hangaard L, Jochumsen MR, Vendelbo MH, Bouchelouche K. Metastases from colorectal cancer avid on 68Ga-PSMA PET/CT. Clin Nucl Med. 2017;42:532-533.
6
Tariq A, Pearce A, Rhee H, Kyle S, Raveenthiran S, Pelecanos A, Gan CL, Goh JC, Wong D, McBean R, Marsh P, Goodman S, Dunglison N, Esler R, Navaratnam A, Yaxley JW, Thomas P, Pattison DA, Roberts MJ. The role of prostate-specific membrane antigen positron emission tomography/computed tomography in primary staging of selected renal tumours: initial experience in a multicentre cohort. Eur Urol Focus. 2024;10:770-778.
7
de Galiza Barbosa F, Queiroz MA, Nunes RF, Costa LB, Zaniboni EC, Marin JFG, Cerri GG, Buchpiguel CA. Nonprostatic diseases on PSMA PET imaging: a spectrum of benign and malignant findings. Cancer Imaging. 2020;20:23.
8
Voter AF, Werner RA, Savas H, Gafita A, Ross AE, Gorin MA, Solnes LB, Pomper MG, Rowe SP, Sheikhbahaei S. A practical guide to the pearls and pitfalls of PSMA PET imaging. Semin Nucl Med. 2024;54:119-131.
